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– ABSTRACT – 
PLACENTAL LOCALIZATION AND PERINATAL OUTCOME. Lucy E.G. Kalanithi, Jessica L. Illuzzi, 
and Errol R. Norwitz. Department of Obstetrics, Gynecology and Reproductive Sciences, Yale 
University School of Medicine, New Haven, CT. 
 
This retrospective case-control study was designed to investigate the relationship between placental localization 
and intrauterine growth restriction (IUGR). Pregnant women with an anatomic survey from January 1, 2000, to 
December 31, 2005, and delivery of the pregnancy at Yale-New Haven Hospital (YNHH) were identified using 
clinical and billing records. Multiple gestation, fetal anomaly, and incomplete medical information were reasons 
for exclusion. Cases (N=69) were consecutive pregnancies with evidence of IUGR (estimated fetal weight <10th 
percentile for gestational age) at last follow-up ultrasound. Randomly selected controls (N=258) from the same 
time period had no evidence of IUGR. Maternal, ultrasound, delivery, and perinatal data were collected by 
retrospective medical record review, and IUGR cases and non-IUGR controls were compared using the 
Student’s t-test, Wilcoxon test, Chi-square analysis, Fisher’s exact test, and ANOVA. Placental location was 
determined from the anatomic survey record (obtained at 18.4 ± 1.2 weeks’ gestation in the IUGR group and 
18.2 ± 1.0 weeks’ gestation in the control group; P=0.18). Multivariate logistic regression with adjustment for 
confounders was used to investigate the association between IUGR and placental localization. Consistent with 
known predictors of IUGR, the IUGR group had a higher proportion of black women (36.4% vs. 19.8%, 
P=0.03), chronic hypertension (26.0% vs. 3.5%, P<0.001), and hypertensive disorders of pregnancy (36.2% vs. 
5.0%, P<0.001). Mean birth weights of IUGR and non-IUGR pregnancies differed by 2 kilograms (3244 ± 625 
grams vs. 1277 ± 637 grams, P<0.001). IUGR infants were more likely to receive antenatal steroids, deliver 
preterm, deliver by cesarean section, and be admitted to neonatal intensive care. In both IUGR and non-IUGR 
pregnancies, the placenta was most commonly anterior or posterior. Unilateral placentas were three times more 
common in the IUGR group than in the non-IUGR group (17.4% vs. 5.0%, P=0.01). IUGR pregnancies were 
over four times as likely as control subjects to have unilaterally-located placentas compared to anterior 
placentas (OR 4.8, 95% confidence interval, 1.9-11.7). Adjusting for ethnicity, chronic hypertension, and 
hypertensive disorders of pregnancy did not affect this finding (OR 4.6, 95% confidence interval 1.6-13.5). In 
conclusion, we compared a group of 69 IUGR pregnancies to 258 non-IUGR controls and found intrauterine 
growth restriction to be associated with unilateral placentation.    
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– INTRODUCTION – 
 
 
Perhaps due in part to the well-publicized research efforts of March of Dimes, it is 
well appreciated that premature birth (birth before thirty-seven weeks’ gestation) 
portends an elevated risk of perinatal mortality and long-term complications. Lesser 
appreciated is the risk to those neonates who, though they may attain adequate 
gestational age before delivery, achieve subnormal growth in utero compared to 
norms for gestational age. Lubchenco et al. (1) were the first to describe a greatly 
elevated risk of neonatal mortality in infants whose birth weight fell below the tenth 
percentile for gestational age, a finding that persisted at all gestational ages at birth: 
thus, their work suggested that regardless of prematurity, small size independently 
predicted neonatal mortality. 
In the forty years since, Lubchenco’s work has been corroborated and further 
elaborated by numerous studies demonstrating not only an elevated perinatal 
mortality rate – in the United States, six to ten times that of normal pregnancies (2) 
– in fetuses with size less than expected for gestational age, but increased neonatal 
morbidity and adverse long-term outcomes in those who survive. Natural and 
iatrogenic preterm birth, neonatal hypoxia, ischemic encephalopathy, poor feeding, 
and metabolic abnormalities including hypoglycemia have all been shown to occur 
more frequently in neonates who fail to achieve gestational-age-appropriate growth 
in utero (3). Long-term sequelae of restricted growth have been less clearly 
elaborated, but may include subnormal height (4) and neurodevelopmental 
abnormalities (5, 6). Additionally, regardless of gestational age, infants with 
subnormal growth in utero carry a higher risk of developing multi-organ system 
2 
adult disease later in life, including cardiovascular disease, hypertension, and type 2 
diabetes mellitus (7-10). 
Appropriate identification and careful management of pregnancies with fetal 
growth restriction may reduce mortality and adverse effects (11, 12). As such, 
pregnancies whose ultrasound-determined estimated fetal weight (EFW) is found to 
be below the tenth percentile for gestational age are now diagnosed with intrauterine 
growth restriction (IUGR) and followed closely. Such pregnancies undergo detailed 
surveillance, aggressive management of maternal disease, support for cessation of 
substance use and good nutrition, antenatal testing, and delivery at institutions with 
neonatology teams equipped to manage perinatal complications (13). 
Since IUGR was first noted to be an important barrier to survival and health, 
many of its determinants have been described. IUGR affects well over 300,000 
pregnancies per year in the United States (14, 15). Around two-thirds of these 
pregnancies are thought to be constitutionally small, with appropriate growth toward 
their genetic growth potential as determined by factors such as parental size and 
ethnicity (15-17). The remaining one-third of IUGR, or more than 100,000 
pregnancies per year in the United States, is thought to result from pathologic factors. 
Fetal growth is affected by a combination of fetal factors, maternal factors, and 
placental factors; IUGR can result from abnormalities in any of these. Pathologic 
IUGR, therefore, does not represent one clinical phenomenon, but rather a 
manifestation of numerous disorders of pregnancy. 
 
Fetal factors associated with IUGR 
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Genetic or structural anomalies. Chromosome or gene abnormalities, including sex 
chromosome disorders and aneuploidy, particularly trisomies 13 and 18, have been 
associated with IUGR (18). IUGR has also been shown to occur at elevated rates in 
fetuses with major structural malformations (19). 
 
Maternal factors associated with IUGR 
Maternal body habitus and nutrition. While growth is strongly influenced by genetic 
factors inherent to the fetus, maternal body habitus also strongly correlates with fetal 
size (20). Maternal weight less than one hundred pounds at conception is associated 
with a two-fold risk of IUGR (18). Further, even given adequate maternal pre-
pregnancy weight, inadequate weight gain during pregnancy puts the fetus at risk for 
growth limitation, likely by limiting substrates available for fetal metabolism (21), a 
result strikingly shown in historical studies of war and famine (22, 23). In order to 
avoid an elevated risk of IUGR, weight gain of 20-25 pounds during pregnancy is 
necessary (15). 
Maternal exposure. Maternal infection, particularly with cytomegalovirus or 
rubella virus prior to twenty weeks’ gestation, is also thought to increase the risk of 
IUGR, an effect theorized to result via induction of cytolysis and capillary endothelial 
damage, which lead to stunted organogenesis (24, 25). The protozoan Toxoplasma 
gondii, parvovirus B19, HIV, and other infectious agents have also been associated 
with IUGR (2). 
 Degree of maternal exposure to certain chemical agents, including 
prescription and non-prescription medications, drugs of abuse, and occupational or 
environmental chemicals, strongly predicts fetal growth. While prenatal and 
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postnatal growth delay are important features of fetal alcohol syndrome (26) 
resulting from excessive alcohol use during the first trimester, alcohol use during the 
second and third trimesters (27, 28), perhaps as few as one to two alcoholic drinks 
per day (29) may restrict growth. One proposed mechanism of action of growth 
restriction, shown in alcohol (24), tobacco (30), and cocaine (31, 32) use, is 
reduction of maternal appetite. Tobacco and cocaine, furthermore, decrease oxygen 
delivery to the fetus due to vasoconstrictive effects (24). Other chemical agents, 
including additional drugs of abuse [e.g., heroin (25)], anticonvulsants [e.g., 
phenytoin (33, 34)], anticoagulants [e.g., warfarin (35, 36)], folic acid antagonists 
[e.g., methotrexate (37, 38)], and occupational or environmental chemicals (39) have 
been associated with IUGR as well. 
Environmental factors. Characteristics of the maternal environment, 
including both geographic location and altitude, have been shown to influence fetal 
growth, as demonstrated by higher average birth weights in populations at sea level 
compared with birth weights in high altitude populations (24, 40). Similarly, 
characteristics of the fetal environment within the uterus are important to growth 
and development. IUGR occurs in up to a quarter of twin pregnancies (22), making it 
ten times more common among twins than among singleton gestations. Defects in 
placental implantation, placental crowding within the uterus, and twin-to-twin 
transfusion are possible mechanisms for this effect (2). 
Maternal disease. Numerous forms of acute and chronic maternal disease 
have been implicated in the development of IUGR, including both pregnancy-
induced hypertension and chronic, or prepregnancy, hypertension, both related 
perhaps to uteroplacental vascular insufficiency (41, 42). Maternal vascular disease 
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may be the most common cause of IUGR in nonanomalous infants (25). 
Preeclamptic pregnancies, also falling in this category, have four times the risk of 
producing an IUGR fetus than do normal pregnancies (43). 
Maternal congenital or acquired thrombophilic disorders, including the 
antiphospholipid antibody syndrome (25) and the prothrombin gene mutation (44, 
45) have likewise been associated with IUGR. Similarly, while gestational diabetes 
and type 2 diabetes, by virtue of maternal and fetal hyperinsulinemia, predispose to 
fetal macrosomia (24), diabetic women with diabetes-related vascular disease, 
particularly in the setting of long-standing type 1 diabetes, are predisposed to 
intrauterine growth restricted pregnancies (46). It is thought that diabetic 
vasculopathy may extend to the placenta, causing pathologic changes that 
compromise placental circulation and thereby restrict fetal size (47). Maternal 
hemoglobinopathies, maternal cyanotic heart disease, and maternal chronic 
pulmonary disease (e.g., cystic fibrosis) also increase the risk of IUGR, possibly by 
limiting fetal oxygenation (48-50). 
 
Placental factors associated with IUGR 
As described above, numerous factors associated with IUGR, including maternal 
malnutrition, infectious agents, and maternal vascular disease, are hypothesized to 
exert their effects on fetal growth by constraining fetal resources, whether by 
restricting metabolic substrates, limiting oxygen availability, or curbing fetal blood 
supply. Given the placenta’s role in fetal blood supply, and hence in both fetal 
nutrient and oxygen delivery, it comes as little surprise that abnormalities of the 
placenta itself elevate the risk of IUGR (51-54). IUGR fetuses often have small 
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placentas, abnormal placental function, or both (55, 56). Chronic placental abruption 
has been associated with IUGR and fetal demise (57). Placenta previa, placental 
infarction, chorioangioma, circumvallate placenta and velamentous cord insertion 
have also been implicated in the development of IUGR (18, 25). 
The worst outcomes have been shown to occur in those growth-restricted 
pregnancies with the highest degree of compromise in uteroplacental blood flow (58, 
59). Simulation models of uteroplacental circulation (60, 61) and studies examining 
the association between placental location and uterine artery Doppler velocimetry 
(62-65) suggest that site of placental attachment in the uterus may be an important 
determinant of placental blood flow. With some variation, such studies have tended 
to classify the site of placental implantation as previa; low-lying (attached in the 
lower uterine segment but not previa); fundal; right, left, or generally “unilateral”; or 
anterior, posterior, or generally “central.” Their findings suggest that abnormal 
uterine artery blood flow is more likely to occur in pregnancies with unilaterally 
located placentas (62, 64, 66). This suggests the possibility that placental location 
might affect fetal growth. 
Site of placental attachment within the uterus has been associated with 
perinatal outcome according to such measures as length of gestation (67, 68), fetal 
position and presentation (69, 70), and development of preeclampsia (64, 71-73)]. 
Despite these findings, the association, if any, between placental localization and 
fetal growth has not been clearly defined. Several studies (74, 75) have found an 
elevated incidence of IUGR in pregnancies with low-lying or previa placentas. 
Kofinas et al. (64) reported that pregnancies with growth restriction and/or 
preeclampsia were more likely than normal pregnancies to have had unilateral 
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placentas compared with central (i.e., anterior or posterior) placentas. Vaillant et al. 
(66), similarly, found increased fetal distress, cesarean deliveries, and IUGR in 
women with unilateral placentas compared with centrally implanted placentas. 
However, Magann et al. (67) studied the relationship between placental location and 
neonatal outcome and, while they found an association between unilateral placental 
location and low Apgar scores, they found no link between placental location and 
IUGR. 
This study was designed to further investigate the relationship between 
intrauterine growth restriction and placental localization in the uterus. 
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– STATEMENT OF PURPOSE – 
 
 
This retrospective case-control study was designed to investigate the relationship 
between ultrasound-documented placental localization and intrauterine growth 
restriction (IUGR) in singleton pregnancies. 
 
Specific aims of the study: 
To determine whether there is an association between placental localization and 













We carried out a retrospective case-control study in which pregnancies with 
persistent IUGR were compared to pregnancies without any evidence of IUGR. We 
reviewed maternal and neonatal medical records to discern placental location, 
maternal demographic and clinical data, and delivery and neonatal outcome data. 
Multivariate logistic regression analysis was used to determine the relationship 
between IUGR and placental location, adjusting for potential confounders. The study 




Subject selection is illustrated in Figure 1. Inclusion criteria were pregnancy with an 
ultrasound performed between 16 and 20 weeks’ gestation (hereafter called the 
“anatomic survey”) at the Yale-New Haven Hospital (YNHH) Perinatology Unit or its 
affiliate at the Long Wharf Medical Center during the period from January 1, 2000 to 
December 31, 2005 (in the case of more than one ultrasound between 16 and 20 
weeks, anatomic survey was defined as the ultrasound performed nearest 18 weeks); 
and either delivery of the pregnancy at YNHH or, in the case of intrauterine fetal 
demise, management at YNHH. Cases, furthermore, were required to have evidence 
of persistent IUGR. IUGR was defined as estimated fetal weight below the 10th 
percentile for gestational age using growth charts appropriate for our patient 
population. Persistent IUGR was defined as evidence of IUGR at the last follow-up 
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ultrasound of the pregnancy. Controls were required to have no evidence of IUGR at 
any ultrasound. Multiple gestations, fetal chromosomal or structural anomalies, 
termination by therapeutic abortion, or incomplete medical data were reasons for 
exclusion. 
Potential IUGR cases were identified using the perinatal ultrasound database 
at Yale-New Haven Hospital. During the study time period, 566 consecutive 
ultrasounds performed at the YNHH Perinatology Unit revealed an EFW <10th 
percentile for gestational age. These ultrasounds corresponded to 350 patients. Of 
these, 69 were included in the study. Of the 281 excluded patients, 187 did not have 
an anatomic survey at YNHH, 24 had structural or chromosomal anomalies, 51 did 
not have evidence of persistent IUGR, 3 ended the pregnancy by therapeutic abortion, 
7 did not deliver at YNHH, and 9 had incomplete medical data available. 
Given 69 IUGR cases, using P<0.05, we calculated that in comparing 
placental location between cases and controls, we would have >80% power to detect 
an odds ratio of 3.0 if we had a 3:1 ratio of controls to cases. To identify potential 
controls, we used the integrated financial and clinical information system (Resource 
Information Management System) at Yale-New Haven Hospital’s Operational 
Finance department. All patients (N=25,660) who were coded and/or charged 
(regardless of ability to pay) for pregnancy ultrasounds during the study time period 
were identified by CPT-4 code (codes 76805 and 76811, delineated in Figure 1). To 
ensure an adequate number of controls, 692 patients were randomly selected from 
among this group. We subsequently excluded 51 patients who did not have records in 
the YNHH perinatal ultrasound database, 274 who did not have an anatomic survey 
at YNHH, 50 patients whose pregnancies had structural or chromosomal anomalies, 
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11 because the pregnancy was not delivered at YNHH, and 23 because there was 
incomplete medical data available. Therefore, a total of 258 controls were included in 
the study. None of the control pregnancies had any evidence of IUGR. 
 
Figure 1:  Method of subject selection 
 
 IUGR cases Non-IUGR controls  
 Consecutive ultrasounds at 
YNHH from Jan 2000 - Dec 
2005 demonstrating singleton 
pregnancies with IUGR (defined 
as EFW <10th percentile for GA)
(N=566 ultrasounds 
by 350 patients) 
Consecutive patients from 
Jan 2000 - Dec 2005 who were 
billed by YNHH using CPT codes 
76805 and 76811 
(N=37,419 ultrasounds 




     





• Subjects who did not have an 
anatomic survey at YNHH 
(N=187) 
• All structural or chromosomal 
anomalies (N=24) 
• Subjects without persistent 
IUGR (N=51) 
• Therapeutic abortion (N=3) 
• Delivery not at YNHH (N=7) 
• Incomplete medical data (N=9)
Excluded:  
• Ultrasound records not in YNHH 
perinatal database (N=51) 
• Subjects who did not have an 
anatomic survey at YNHH (N=274)
• All structural or chromosomal 
anomalies (N=50) 
• Multiple gestations (N=11) 
• Delivery not at YNHH (N=25) 
• Incomplete medical data (N=23) 
 
     
 IUGR cases 
included in the final analysis 
(N=69) 
Non-IUGR controls 





Reasons for exclusion are listed in order of application (e.g., after potential subjects without 
anatomic surveys at YNHH were excluded, the remaining potential subjects were examined 
for structural or chromosomal anomalies). Thus, while a pregnancy may have had more than 
one reason for exclusion from the study, the first reason encountered is designated here. 
Abbreviation: IUGR, intrauterine growth-restricted; YNHH, Yale-New Haven Hospital; EFW, 
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estimated fetal weight; GA, gestational age. CPT-4 code 76805 is defined as "Ultrasound, 
pregnant uterus, real time with image documentation, fetal and maternal evaluation, after 
first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation." 
CPT-4 code 76811 is defined as "Ultrasound, pregnant uterus, real time with image 
documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, 




For each pregnancy, we recorded placental location as noted at the anatomic survey 
and additionally, if the anatomic survey was not the last ultrasound, as noted at the 
last follow-up ultrasound. In the multivariate analysis, placental location was 
determined by the anatomic survey. We chose to define placental location using 
anatomic survey for several reasons. Many healthy pregnancies have only one 
ultrasound around 18 weeks’ gestation, without further follow-up ultrasounds unless 
clinically indicated. Choosing only control pregnancies with later ultrasounds, 
therefore, might have skewed the control group to include a higher proportion than 
would be expected of complicated pregnancies, limiting the power to detect a 
difference between the two groups or to generalize any findings to healthy 
populations. Thus, the anatomic survey was used to determine placental location in 
all pregnancies studied, despite many pregnancies having one or more follow-up 
ultrasounds after the anatomic survey. Determining placental location for all 
subjects at the same gestational age ensured that our findings were not influenced by 
a possible association between gestational age and assessment of placental location. 
 In each ultrasound report, one or more of the following placental locations was 
noted: anterior, posterior, unilateral, fundal, low-lying, and previa. If there was any 
confusion about reported placental location, or if placental location was not noted in 
the anatomic survey report, images were reviewed by a single perinatologist (E.R.N.) 
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who was blinded to the clinical circumstances of the patient. For the purposes of our 
analysis, each placenta was classified (see Figure 2) as previa (including previa, 
total previa, partial previa, and marginal previa, regardless of anteroposterior or 
lateral position), low-lying (regardless of anteroposterior position), unilateral 
(including all non-previa and non-low-lying placentas designated as having a left or 
right lateral component, regardless of anteroposterior or fundal position), fundal 
(including all remaining placentas with a fundal component, regardless of 
anteroposterior position), anterior, or posterior. 
 


















For the purpose of analysis, we used six designations of placental location, illustrated above, 
into which all subclassifications recorded at anatomic survey had been reclassified. 
* includes fundal, fundal/anterior, and fundal/posterior 
† includes left, right, left/fundal, right/fundal, left/anterior, right/anterior, right/posterior, and 
right/fundal/anterior 
‡ includes anterior 
§ includes posterior 
¶ includes low-lying/anterior and low-lying/posterior 
†† includes previa, posterior/previa, left/total previa, anterior/partial previa, posterior/partial 
previa, anterior/marginal previa, and posterior/marginal previa 
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Maternal race (white; black; Hispanic; Asian; or other, including Native 
American, southeast Asian, and mixed race) was abstracted from the Resource 
Information Management System database. All other clinical, demographic, and 
pregnancy outcome data were abstracted from maternal and neonatal medical 
records, including maternal age at anatomic survey; gravity; parity; chronic 
(pregestational) hypertension; pregestational or gestational diabetes mellitus; 
hypertensive disorders of pregnancy (including pregnancy-induced hypertension, 
preeclampsia, and HELLP); alcohol, tobacco, or illicit substance (e.g., cocaine, heroin) 
use as determined by patient report; methadone use; gestational age at anatomic 
survey, last follow-up ultrasound, and delivery; intrauterine fetal demise; 
intrapartum steroid administration to promote fetal lung maturity (whether one dose 
or a full course); indication for delivery; mode of delivery; birth weight; Apgar scores 
at 1 and 5 minutes; admission to neonatal intensive care; and neonatal demise 
(defined as death prior to hospital discharge). 
 
Analytic methods 
Statistical analyses were performed using the SAS 9.1 statistical program. The Chi-
square test, Wilcoxon test, ANOVA, Student’s t-test, or Fisher’s exact test were used 
to compare characteristics of the case and control groups. Continuous variables were 
examined for normal distribution; if found to be normal, means and standard 
deviations were compared using the Student’s t-test or Fisher’s exact test. For 
continuous variables that were not normally distributed, results were reported as 
median (interquartile range), where interquartile range is the range of values 
spanning the 25th to 75th percentile, and compared using the Wilcoxon test. 
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Multivariate logistic regression analysis was used to examine the relationship 
between placental location and IUGR, adjusting for potential confounders after 
creating the most parsimonious model using backwards stepwise elimination. We 
estimated 95% confidence intervals and results were considered significant at 
P<0.05. 
 
Distribution of work 
Contact with the Human Investigation Committee of the Yale School of Medicine 
regarding initial and ongoing study approval was by Errol Norwitz, M.D., Ph.D., of 
the Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale 
School of Medicine, and Lucy Kalanithi. Lists of potential subjects were generated by 
Wendy Shaffer, RDMS, of the Yale Perinatal Unit via the Yale-New Haven Hospital 
perinatal ultrasound database and by Joan Rimar, D.N.SC., Clinical Coordinator, 
Finance, Yale-New Haven Hospital, via the Resource Information Management 
Systems database. Controls were randomly selected using SAS 9.1 by Jessica Illuzzi, 
M.D., M.S., of the Department of Obstetrics, Gynecology, and Reproductive Sciences 
at the Yale School of Medicine. Data were collected by Lucy Kalanithi. Data analysis 
was performed by Jessica Illuzzi and Lucy Kalanithi. 
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Table 1 compares the maternal demographic and clinical characteristics of the 
IUGR and non-IUGR pregnancies. The groups did not differ with respect to maternal 
age, gravity, parity, and body mass index. Racial characteristics of the groups did 
differ, however. Though each group was made up of about half white women, black 
women made up a higher proportion of the IUGR group (36.4% vs. 19.8%, P=0.03). 
 
Table 1. Maternal demographic and clinical characteristics of the 327 








Maternal age (years) 29.2 ± 6.8 29.4 ± 5.9 P=0.75 
Gravity* 3 (1) 2 (3) P=0.29 
Parity† 1 (2) 1 (1) P=0.12 
Race‡ (% [N])   P=0.03 
  White 48.5% [125] 47.0% [31]  
  Black 19.8% [51] 36.4% [24]  
  Hispanic 22.9% [59] 12.1% [8]  
  Asian 






Gestational age at 
anatomic survey (weeks) 
 
18.2 ± 1.0 
 
18.4 ± 1.2 
 
P=0.18 
Gestational age at last 
ultrasound  (weeks) 
29.1 (19.0-35.0) 32.0 (28.9-35.3) P<0.001 
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Total number of 
ultrasounds 
2 (1-4) 4 (3-7) P<0.001 
Body mass index¶ 30.5 (27.5-35.0) 29.3 (27.1-36.1) P=0.39 
Diabetes (% [n]) 
   No diabetes 
   Pregestational DM 











Chronic HTN (% [N])** 
   No hypertension 
   Untreated hypertension 











Hypertensive disorder of 
pregnancy (% [N]) 
 





Smoking†† (% [N]) 22.0% [54] 28.8% [19] P=0.25 
Alcohol use‡‡ (% [N]) 2.8% [7] 6.0% [4] P=0.26 
Illicit drug or 
methadone use§§ (% [N]) 
4.8% [12] 7.4% [5] P=0.37 
 
Results are expressed as mean ± standard deviation, median (interquartile range), or % [N]. 
Abbreviation: IUGR; intrauterine growth-restricted; DM, diabetes mellitus; HTN, hypertension. 
* 3 controls did not have gravity recorded. 
† 5 controls and 2 cases did not have parity recorded. 
‡ 3 cases did not have race recorded. 
¶ 38 controls and 22 cases did not have height and/or weight recorded. 
** In all, there were 9 controls with chronic hypertension and 18 cases with chronic 
hypertension; of those, 1 case and 1 control did not have medication information available. 
†† 13 controls and 3 cases did not have smoking status recorded. 
‡‡ 10 controls and 2 cases did not have alcohol use recorded. 
§§ 10 controls and 2 cases did not have illicit drug and/or methadone use recorded. 
 
 Anatomic surveys are generally performed between the sixteenth and 
twentieth week of gestation; we excluded any subjects who did not have an 
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ultrasound during this time period. As expected, therefore, our subjects underwent 
anatomic survey at 18.2 ± 1.0 weeks’ gestation (non-IUGR controls) and 18.4 ± 1.2 
weeks’ gestation (IUGR cases, P=0.18). After the anatomic survey, 66% (170/258) of 
the control pregnancies underwent one or more follow-up ultrasounds [with a 
median of 2 ultrasounds total (interquartile range 1-4)]. Thus, gestational age at the 
last ultrasound was bimodally distributed for the control group, with a peak at 
around 18 weeks’ gestation and a peak at around 35 weeks (median 29.1 weeks, 
interquartile range 19.0-35.0). Follow-up ultrasounds for the non-IUGR group did 
not detect IUGR; they were done for reasons such as history of cervical 
incompetence, abnormal triple serum screening, maternal exposure to teratogenic 
medications, and placenta previa. In the IUGR group, every pregnancy had at least 
one follow-up ultrasound after anatomic survey, with a median of 4 (3-7) 
ultrasounds total (P<0.001 compared with controls, Wilcoxon test) and the last 
follow-up ultrasound occurring at 32.0 (28.9-35.3 weeks’ gestation (P<0.001 
compared with controls, Wilcoxon test) [both distributed normally but reported as 
median (interquartile range) as for the non-normally distributed controls]. 
The groups had comparable proportions of mothers with diabetes mellitus: 
7.0% (18/258) of the control mothers and 5.8% (4/69) of the mothers with IUGR 
pregnancies had either pregestational or gestational diabetes (P=0.73). There was a 
trend toward a higher proportion of pregestational diabetic mothers among IUGR 
cases (2.9% of all cases vs. 0.8% of controls) and a higher proportion of gestational 
diabetic mothers in the control group (6.2% of all controls vs. 2.9% of cases) 
(P=0.21). 
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There was a marked difference between the two groups in the incidence of 
maternal hypertensive disorders. While fewer than 1 in 20 (9/258, or 3.5%) of 
control mothers had chronic, or pregestational, hypertension, 1 in 4 of the mothers 
in the IUGR group did (18/69, or 26.1%, P<0.001). In the control group, 1.6% of all 
mothers were hypertensives who took no medication to control their blood pressures 
and 1.6% were hypertensives on antihypertensive treatment. The IUGR group was 
quite different (P<0.001): 5 out of every 6 hypertensive mothers in that group, or 
20.3% of the entire IUGR group, were on antihypertensive medications. 
 Similarly, hypertensive disorders of pregnancy (including pregnancy-induced 
hypertension, preeclampsia, and HELLP) occurred in 36.2% (25/69) of the IUGR 
pregnancies, a rate 7 times higher than in the non-IUGR group (in which 13/258 
pregnancies, or 5.0%, were complicated by hypertensive disorders of pregnancy; 
P=<0.001). 
 The proportion of women who used tobacco, alcohol, or illicit drugs was 
comparable between the two groups: 28.8% (19/69) of the IUGR group and 22.0% 
(54/258) of the control group and reported smoking at some point during the 
pregnancy (P=0.25); 6.0% (4/69) of the IUGR group and 2.8% (7/258) of the control 
group reported drinking alcohol at some point during the pregnancy (P=0.26, 
Fisher’s exact test); and 7.4% (5/69) of the IUGR group reported illicit drug and/or 
methadone use, while 4.8% (12/258) of the cases did (P=0.37, Fisher’s exact test). 
 
Placental localization 
The distribution of placental locations, as determined at anatomic survey, differed 
between the two groups (Table 2). In both the IUGR and non-IUGR pregnancies, 
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placentas were most commonly located anteriorly, with anterior accounting for 
roughly half (48.1%) of placental locations in the non-IUGR group and around a 
third (34.8%) of the IUGR group. Unilateral placentas were three times more 
common, however, in the IUGR group than in the non-IUGR group (17.4% vs. 5.0%).  
 









Anterior 48.1% [124] 34.8% [24] 
Posterior 35.2% [91] 31.9% [22] 
Fundal 7.0% [18] 10.1% [7] 
Unilateral 5.0% [13] 17.4% [12] 
Low-lying 2.7% [7] 1.5% [1] 





Results are expressed as % [N]. Abbreviation: IUGR, intrauterine growth-restricted. 
 
 
Posterior placentas accounted for 35.2% of the non-IUGR group and 31.9% of the 
IUGR group; fundal placentas 7.0% of the non-IUGR group and 10.1% of the IUGR 
group; low-lying placentas 2.7% of the non-IUGR group and 1.5% of the IUGR group; 
and placenta previa 1.9% of the non-IUGR group and 4.4% of the IUGR group. 
 We also analyzed the data to determine if the designation of placental location 
persisted from 18-weeks’ gestation to the last follow-up ultrasound. As stated 
previously, only 66% of control group pregnancies had a follow-up ultrasound 
performed after the anatomic survey. Using data from follow-up ultrasounds, 89.7% 
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(70/78) of placentas classified as anterior at anatomic survey continued to be 
classified as anterior at the last follow-up. Of posterior placentas, 75.4% (46/61) 
remained posterior at last follow-up ultrasound, while only 11.1% (1/9) of unilateral 
placentas remained unilateral, and no fundal (0/10), low-lying (0/7), or previa (0/5) 
placentas persisted. All 69 of the IUGR pregnancies had at least one follow-up 
ultrasound; 3 of them, however, did not have placental location recorded at the last 
follow-up ultrasound. In the rest of the IUGR group, 70.8% (17/24) of anterior 
placentas remained anterior, 81.0% (17/21) of posterior placentas remained 
posterior, 18.2% (2/11) of unilateral placentas remained unilateral, and 33.3% (2/6) 
of fundal placentas remained fundal. One low-lying placenta was identified in the 
IUGR group; it did not persist. Of three previa placentas, one continued to have 
evidence of previa at last follow-up ultrasound. 
 
Delivery and neonatal outcomes 
Mean birth weights between the two groups of pregnancies differed by 2 kilograms: 
the non-IUGR infants weighed 3244 ± 625 grams, while the growth restricted infants 
weighed 1277 ± 637 grams (P<0.001). By several other measures, the IUGR 
pregnancies were more complicated than the non-IUGR pregnancies (see Table 3). 
Prior to delivery, over half the IUGR group (57.6%) received at least one dose of 
intrapartum steroids, while fewer than 1 in 20 (3.1%) of the controls were given 
steroids (P<0.001). The control pregnancies tended to be delivered at term (mean 
39.1 ± 2.2 weeks’ gestation), while the IUGR pregnancies delivered prematurely 
(mean 32.5 ± 4.4 weeks, P<0.001). Over two-thirds of IUGR pregnancies (70.4%) 
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were delivered by cesarean section, compared with fewer than one-third (28.3%) of 
the non-IUGR group (P<0.001). 
 
Table 3. Delivery and perinatal characteristics of the 327 pregnancies, 










IUFD 0.4% [1] 2.9% [2] P=0.11 
Antenatal 
steroids* 
3.1% [8] 57.6% [38] P<0.001 
Cesarean delivery 28.3% [73] 72.5% [50] P <0.001 
Gestational age  
at delivery (weeks) 
39.1 ± 2.2 32.5 ± 4.4 P <0.001 
Birth weight 
(grams) 
3244 ± 625 1277 ± 637 P <0.001 
Gender (female) 55.8% [144] 58.0% [40] P=0.75 
Apgar score† 
<5 at 1 minute 












16.0% [41] 92.5% [62] P <0.001 
Neonatal demise 0.8% [2] 4.4% [3] P =0.07 
 
Results are expressed as mean ± standard deviation or % [N]. Abbreviation: IUFD, 
intrauterine fetal demise; IUGR, intrauterine growth-restricted. 
* For 3 cases, data on whether antenatal steroids were administered was not available. 
† 2 controls and 3 cases did not have Apgar scores recorded. 
‡ For 1 control and 3 cases, data on the necessity of NICU admission was not available. 
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The indications for delivery in each of the two groups were as follows: in the 
control group, 53.4% of deliveries followed spontaneous labor (135/253), 12.5% were 
electively delivered at term (32/253), 5.5% were delivered for oligohydramnios 
(14/253), 5.1% for non-reassuring fetal testing (13/253), 4.7% for hypertensive 
disorders of pregnancy (12/253), 4.3% for failure to progress (11/253), 4.3% because 
they were post-due (11/253), 2.4% for premature rupture of membranes (PROM) 
(6/253), 1.6% for preterm premature rupture of membranes (pPROM) (4/253), and 
7.9% other reasons (including abruption and polyhydramnios). In the IUGR group, 
38.2% were delivered due to IUGR (26/68), 51.5% due to non-reassuring fetal 
testing (35/68), 22.1% for hypertensive disorders of pregnancy (15/68), 7.4% for 
oligohydramnios (5/68), 5.9% for placental abruption (4/68), 4.4% for spontaneous 
labor (3/68), 2.9% for preterm premature rupture of membranes (pPROM) (2/68), 
2.9% following intrauterine fetal demise (2/68), and 1.5% (1/68) spontaneously at 
term (percentages add up to greater than 100% because some pregnancies had more 
than one delivery indication). 
The IUGR infants had less stable neonatal periods as well (Table 3). They 
were more likely to have Apgar scores of less than 5 at 1 minute of life (16.7% in the 
IUGR group vs. 2.3% in the non-IUGR group, P<0.001 by Fisher’s exact test), 
though by 5 minutes of life they did not differ from the non-IUGR group by this 
measure. Greater than 9 out of 10 of the IUGR infants received immediate postnatal 
care in the neonatal intensive care unit, while greater than 8 out of 10 of the other 
group went to the well baby nursery following delivery (92.5% vs. 16.0% admitted to 
neonatal intensive care, P<0.001). Though the proportion did not reach statistical 
significance, 2.9% (2/69) of IUGR pregnancies ended in intrauterine fetal demise, 
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compared with 0.4% (1/258) of control pregnancies (P=0.11, Fisher’s exact test). 
Similarly, 4.4% (3/69) of IUGR infants died before hospital discharge, compared 
with 0.8% (2/258) of controls (P=0.07, Fisher’s exact test). 
 
Placental localization and intrauterine growth restriction 
Pregnancies with IUGR were over four times as likely as control pregnancies to have 
had unilaterally-located placentas compared to anterior placentas (odds ratio 4.8, 
95% confidence interval, 1.9-11.7) (Table 4). Adjusting for ethnicity, chronic 
hypertension, and hypertensive disorders of pregnancy (no other variables were 
found to be statistically significant confounders) did not affect this finding (odds 



















Table 4. Association between intrauterine growth restriction at latest follow-up 
ultrasound and placental location as determined at 16-20 week anatomic 
survey: multivariate logistic regression 
 
 
 Unadjusted Adjusted* 
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Placental location OR 95% CI OR 95% CI 
Anterior 1.0 Reference 1.0 Reference 
Posterior 1.3 0.7-2.4 1.0 0.4-2.2 
Fundal 2.0 0.8-5.3 3.1 1.0-9.6 
Unilateral 4.8 1.9-11.7 4.6 1.6-13.5 
Low-lying 0.7 0.1-6.3 0.4 0.0-4.7 
Previa 3.1 0.7-13.8 2.6 0.4-18.7 
 
*Adjusted for ethnicity, chronic hypertension, and hypertensive disorders of pregnancy 
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– DISCUSSION – 
 
 
This retrospective case-control study compared intrauterine growth-restricted 
(IUGR) pregnancies with non-growth-restricted pregnancies and found IUGR to be 
associated with attachment of the placenta to a lateral (i.e., right or left) uterine wall 
during the second trimester. More specifically, the odds of having had a unilateral 
placenta (versus the most common placental location, anterior) were over four times 
greater in IUGR pregnancies compared with non-IUGR controls. IUGR was not 
associated with other placental locations (anterior, posterior, fundal, low-lying, or 
previa). 
Our finding suggests that lateral placentation predisposes to IUGR. 
Alternative explanations for the finding seem less likely. Given its statistical 
significance (odds ratio 4.6, 95% confidence interval 1.6-13.5), which persists after 
adjustment for potential confounders, the result is unlikely to be due to chance. We 
were careful to record and include in our multivariate logistic regression analysis a 
number of important clinical characteristics (e.g., hypertensive disorders of 
pregnancy) that are associated with IUGR in the medical literature and which could 
potentially confound our analysis, and in the final analysis we adjusted for all 
significant confounders (chronic hypertension, hypertensive disorders of pregnancy, 
and ethnicity). It is possible that our results could be confounded by a known factor 
associated with IUGR not included in our data (e.g., presence of maternal 
thrombophilia), but this would be less likely given that such factors are not known to 
be linked to placental location. There may also exist an as-yet-unknown confounder 
(for example, a characteristic of the uterine myometrium) that predisposes to both 
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unilateral placentation and IUGR, and which would thereby discount a cause-effect 
relationship between unilateral placentation and IUGR. Prior studies have not 
revealed such a mechanism. 
Therefore, we believe our findings suggest that some aspect of placental 
implantation in the lateral uterus makes it less favorable for fetal growth than 
implantation in other sites. One possible explanation for this is grounded in prior 
studies demonstrating differential placental blood flow according to placental 
location. Prior studies have suggested, using Doppler velocimetry, an association 
between unilaterally-located placentas and abnormal uterine artery flow velocity 
(64). 
The maternal blood supply to the placenta derives mainly from the uterine 
arteries, with additional supply from the ovarian arteries. The right and left uterine 
arteries each have many branches that supply the ipsilateral side of the uterus (76). 
In some patients, arcuate branches of the right and left uterine arteries cross to the 
contralateral side and create major anastomoses (77). In pregnancies with unilateral 
placentas, uterine artery resistance is lower in the ipsilateral vs. contralateral uterine 
artery, while in pregnancies with centrally located placentas resistance is similar 
between the two uterine arteries (62, 65, 66).  Ito et al. (62) interpreted this finding 
in the context of an electrical equivalent circuit model of uteroplacental circulation 
(61) and suggested that the decreased placental-side uterine artery resistance may 
reflect decreased uteroplacental blood flow volume in unilaterally situated placentas. 
Kofinas (64), further, suggested an anatomic mechanism by which decreased blood 
flow to a unilaterally located placenta could occur. Perhaps centrally located 
placentas receive adequate blood flow from both uterine arteries by virtue of their 
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position. In contrast, unilaterally located placentas may depend on a high degree of 
anastomosis between the ipsilateral and contralateral uterine arteries in order to 
receive adequate blood supply. Therefore, any deficiency in collateral circulation 
could lead to decreased blood flow, and, therefore, a higher risk of growth restriction, 
in pregnancies with unilateral placentas. 
Indeed, the abnormal waveforms in the uterine and uteroplacental circulation 
that were demonstrated to occur more commonly with unilateral placentation have 
since been associated with placental ischemia on postpartum placental pathologic 
examination (78) and have been corroborated as important predictors of IUGR (63, 
79). Thus, given that uteroplacental insufficiency is a well-established and common 
cause of growth restriction in utero, abnormal blood flow is a feasible mechanism by 
which unilateral placentation could predispose to IUGR. This theory is bolstered by 
analogous reports in the medical literature regarding preeclampsia, which shares 
with IUGR the common pathologic mechanism of uteroplacental insufficiency and 
has also associated with unilateral placental implantation (71). 
The association of placental location and IUGR has been examined before 
with contradictory results. Kofinas et al. (64) used a case-control design to compare 
placental location in pregnancies with IUGR and/or preeclampsia to placental 
location in normal pregnancies. No odds ratio was reported, but they found that in 
the presence of preeclampsia and/or IUGR, up to 75% of pregnancies had 
unilaterally located placentas and 25% central placentas, whereas in the absence of 
these two conditions, 51% of the patients had unilateral and 49% central placentas 
(P<0.02). Similarly, Vaillant et al. (66) found an increased history of fetal distress, 
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cesarean deliveries, and IUGR in women with unilateral placentas compared with 
centrally implanted placentas. 
A more recent study by Magann et al. (67), however, examined second 
trimester placental location and a variety of adverse pregnancy outcomes, with a 
result contradictory to the prior studies’. Though this group found an association 
between unilateral implantation and low Apgar scores (<7) at 1 and 5 minutes, they 
found no association between any placental location and IUGR. In fact, they found 
unilateral placentas to be associated with an increased risk of macrosomia, 
suggesting larger neonates in this group. 
Several additional studies have looked specifically at the relationship between 
IUGR and low-lying or previa placentas via retrospective analysis of large groups of 
pregnancies with these uncommon placental locations. Strong associations between 
IUGR and low-lying (75) or previa (74, 80) placentas were found in some of these 
studies. Others found a weak association (81) or no association (82, 83) Our study 
did not find an association between low-lying or previa placentas and IUGR. Because 
of the very small number of low-lying (8 total) and previa (8 total) placentas 
included in our study, we may have lacked statistical power to detect an association. 
Our study lends weight to the findings associating IUGR with unilateral 
placentation. We believe our data set to be robust and our finding to be valid, 
particularly given its significance despite a relatively small sample size and our strict 
definition of IUGR (with growth <10th percentile required to persist through the 
latest follow-up ultrasound), which may have increased our ability to detect an 
association. 
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As regards the clinical and demographic variables we measured, we found 
several differences between the IUGR and non-IUGR groups. Race was associated 
with IUGR, with a significantly higher proportion of black mothers in the IUGR 
group. The association between black race and IUGR has been demonstrated in at 
least one large epidemiologic study (84). Our observations that hypertensive 
disorders and pregestational diabetes were more common among IUGR pregnancies 
than non-IUGR controls are consistent with well-described associations of IUGR 
with maternal vascular disease (25, 41, 43) and diabetic vasculopathy (46). 
There was also a trend toward a higher proportion of gestational diabetic 
mothers in the control group, and a trend toward a higher proportion of 
pregestational diabetic mothers in the IUGR group. Interestingly, these trends are 
consistent with known associations between gestational diabetes and fetal 
macrosomia (24), and between diabetes-related vascular disease (of the type that 
develops in the setting of longer-standing diabetes) and fetal growth restriction (46). 
Perhaps due to a relatively small number of mothers with diabetes, however, these 
differences were not significant. 
Smoking (30), alcohol use (27-29), and illicit substance use (25, 31, 32) have 
been associated with IUGR in large epidemiologic studies. Substance use was not, 
however, associated with IUGR in this study. This may be because we measured 
substance use as a categorical variable (i.e., any substance use at all vs. no substance 
use at all). For example, women who reported drinking until they learned they were 
pregnant, as well as those who reported drinking one drink per week, one drink per 
day, or many drinks per day throughout pregnancy were all classified together as 
drinkers. Nondrinkers were those without any alcohol use at all. A dose-response 
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effect of alcohol use in pregnancy has been reported (29) such that the percentage of 
IUGR newborns increases sharply with increasing maternal alcohol intake, while the 
consumption of less than one drink daily may have little effect on intrauterine 
growth. Therefore, because we could not analyze substance use as a continuous 
variable or a categorical variable indicating substantial use, a relatively high 
proportion of low-dose substance users may have diluted our ability to detect an 
association with IUGR if one existed. 
Not surprisingly, we found a marked difference in birth weight between the 
IUGR and non-IUGR pregnancies. The mean birth weight of the IUGR infants fell 
well below the clinically significant category of low birth weight (<2500g), which, 
like IUGR, portends a substantially increased risk of morbidity and mortality (85, 
86). The observation that pregnancies with IUGR received intrapartum steroids and 
were delivered earlier than non-IUGR infants is consistent with current obstetric 
management, which encourages active intervention and delivery of IUGR fetuses 
once a favorable gestational age is reached or fetal growth ceases. The great majority 
of IUGR neonates we studied were admitted to the neonatal intensive care unit; this 
is also consistent with current management of IUGR pregnancies, though this may 
also have been related to the group’s low gestational ages, given that IUGR 
pregnancies tended to deliver prematurely. The high proportion of IUGR 
pregnancies delivered by cesarean section is likely related to the high proportion of 
deliveries in that group (51.5%) for non-reassuring fetal testing. 
We identified placental location by retrospective review of the anatomic 
survey performed between 16 and 20 weeks’ gestation. Because many healthy 
pregnancies have no further follow-up scans after that time, we chose to determine 
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placental location during the second trimester so that our method remained constant 
among all pregnancies. At least two more recent studies investigating the effects of 
placental location on pregnancy outcome have used a similar approach, with 
placental location determined at 18 weeks (87) or between 14 and 22 weeks (67). 
The distribution of placental locations in the pregnancies we studied was 
consistent with several large studies of second trimester placental location (73, 88, 
89), in which most placentas were found to be located anteriorly or posteriorly in the 
upper uterine segment. We found, as prior studies have, that anterior and posterior 
implantation sites were not associated with IUGR. It may be that blastocysts are 
more likely to implant in uterine sites that are favorable to fetal growth, or that 
implantation in sites less favorable to growth [as has been shown, for example, in 
studies of implantation in the region of a uterine septum (90)] is associated with 
spontaneous abortion, making placental attachment in such areas less common. 
Further studies could expand on this observation. 
Though our study investigated the relationship between second trimester 
placental location and IUGR, we were interested to see if there was some degree of 
placental “migration” following the anatomy scan. A prior case-control study (64) 
evaluated 300 pregnancies and found no difference in the incidence of placental 
laterality (vs. centrality) between pregnancies <28 weeks’ gestation and those of >28 
weeks. In contrast, a larger prospective study (88) identified placental location at 18 
weeks and compared it to results of serial assessments throughout the pregnancy, 
demonstrating that 16.9% of non-low-lying posterior placentas and 4.9% of anterior 
placentas migrated to a fundal position by 34 weeks. Of low-lying placentas (called 
anterior low or posterior low in the referenced study) identified at 18 weeks, 97.8% 
33 
were no longer low-lying toward the end of the pregnancy; 55.5% of previas at 18 
weeks remained previa by 34 weeks’ gestation. We found similar rates of shifting 
classification of placental location over time. Perhaps placental location is more 
difficult to identify in a smaller gravid uterus, and therefore assessment of location 
becomes more specific and thus may change as the uterus grows. Further studies 
may better elucidate placental “migration” and determine if there is also an 
association between IUGR and placental location in the third trimester, which, like 
the second trimester, is an important period of fetal growth. 
We regard the validity of the data set to be a major strength of our study. The 
IUGR group differed significantly from the control group with respect to maternal 
race, chronic hypertension, hypertensive disorders of pregnancy, gestational age at 
delivery, and birth weight, among other variables. These characteristics have well-
known associations with IUGR, as previously demonstrated in the medical literature. 
The validity of our data set by these measures gives us confidence in the validity of 
the association we detected between IUGR and second trimester placental location. 
Our study had several limitations. The case-control design allowed us to 
detect an association between IUGR and unilateral placentation. Though we 
discussed the possibility of a cause-effect relationship, our study design precludes 
anything beyond speculation. Further, a number of subjects (N=19) were excluded 
from the multivariate regression analysis, in which we controlled for potential 
confounders, because one or more data points were missing (e.g., maternal race). 
Ideally, we would have included all subjects in this adjusted analysis, though we do 
not suspect that the excluded subjects were different from included subjects in a way 
that would affect our findings. 
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In summary, we completed a retrospective case-control study comparing 69 
pregnancies with intrauterine growth restriction (IUGR) to 258 non-growth-
restricted pregnancies treated at the same institution during the same time period. 
We found, as two prior studies have, an association between IUGR and second 
trimester unilateral placentation. After adjusting for confounders, IUGR pregnancies 
were over four times as likely as control subjects to have had unilaterally located 
placentas compared to anterior placentas, an association we believe may relate to 
differential placental blood flow according implantation site. Additional research is 
necessary to further confirm this observation, and if confirmed, to elucidate its 
mechanism and determine whether pregnancies with unilateral placentas require 
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